Cerebricon: Press Releases
Cerebricon to Exhibit at European Neurotech Investing & Partnering Summit
Cerebricon is proud to be a key sponsor of this year's European Neurotech Investing & Partnering Summit. The conference takes place at the Scandic Grand Marina and Congress Center in...
Schedule of Cerebricon Poster Scientific Presentations at the SFN 2011
Cerebricon (Charles River Discovery Services, Finland) is very proud to be involved in the presentation of eight scientific poster presentations at this year’s SFN annual meeting being held...
Cerebricon to Exhibit at the AAICAD 2011 in Paris
Cerebricon and Charles River will be attending AAICAD, Alzheimer's Association International Conference on Alzheimer's Disease 2011, in Paris, France. The conference will take place at the...
Cerebricon Sponsors 2011 World Orphan Drug Congress in Geneva, Switzerland
As part of Cerebricon's ongoing commitment to those developing drugs for orphan indications we are proud to sponsor the Orphan Drug Congress in Geneva, Switzerland. Cerebricon (part of...
Cerebricon to Present Two Scientific Posters at the 10th International Conference on AD/PD 2011
Cerebricon is to present two scientific posters at the 10th International Conference on Alzheimer's and Parkinson's Diseases AD/PD 2011, which will be held 9-13 March in Barcelona, Spain. You...
Cerebricon to Present Three Scientific Posters at the 6th Annual Huntington's Disease Therapeutics Conference
Cerebricon will participate in and present three scientific posters at the 6th Huntington's Disease Therapeutics Conference, which will take place 7-10 February in Palm Springs, US. The...
Cerebricon Announces the Release of Three Experimental Autoimmune Encephalomyelitis Mouse Models for the In Vivo Study of Multiple Sclerosis
Cerebricon is pleased to provide three new in vivo models for the study of Multiple Sclerosis (Ms). The models incorporate various approaches to the induction of Ms-like symptoms in mice....
Cerebricon Announces Licence Agreement With UCL for Commercialisation of a New Model of ADHD
Cerebricon is proud to announce that it has completed negotiations with University College London (UCL) and UCL Business and has acquired an exclusive licence in order to be able to breed and...
Cerebricon Ltd. Obtains 3rd Party Transgenic SOD1 License for the Study of ALS
Cerebricon Ltd is pleased to announce that it has completed negotiations with Northwestern University, MIT and HFMC in order to obtain a license concerning the ability to offer the SOD1 G93A...
Cerebricon Ltd. and Pronexus Analytical AB Sign Exclusive Agreement in the Areas of Marketing and Scientific Collaboration
Cerebricon Ltd and Pronexus Analytical AB are pleased to announce that they have completed an agreement that allows Cerebricon Ltd. exclusive license to market Pronexus Analytical Services to...
Cerebricon Ltd. and Neurological Models Inc. Announce Strategic Alliance.
Cerebricon and Keith Baker, the former president of Neurological Models today have announced that they have formed a strategic alliance that will focus their combined efforts to promote...
Cerebricon Ltd. and Neuromolecular Models Inc. (Danvers, MA) Announce Strategic Alliance
Cerebricon and Neuromolecular Models today have announced that they have formed a strategic alliance that will see the two companies expand their relationship to encompass projects related...
Cerebricon to Exhibit at the 2007 Society for Neuroscience (SFN) Annual Meeting in San Diego
Cerebricon will be attending this years Society for Neuroscience annual meeting in San Diego, California. Cerebricon are excited to announce that they will be exhibiting five posters at...
Cerebricon Increases Focus on Translational Aspects of Preclinical Drug Development: Imaging/MRI/MRS
Cerebricon is investing significant resources into developing their already established imaging capability at their central laboratories in Kuopio, Finland. The inclusion of...
Cerebricon Increases Focus on Imaging Technology
Cerebricon is investing significant resources into developing their already established imaging capability at their central laboratories in Kuopio, Finland. The inclusion of...
Cerebricon Announces Updates To Product Portfolio
Cerebricon is pleased to announce the following additions to its portfolio of in vivo models: (EAE) Model for multiple sclerosis R6/2 Transgenic model for Huntington's disease In vitro...
Cerebricon to Exhibit at the BIO-Europe Spring 2007 in Milan, Italy.
Jan 22th, 2007 Kuopio, Finland - Cerebricon Ltd. announces that it will be exhibiting at this years BIO-Europe Spring 2007 meeting. The meeting takes place at the Milan Convention Centre...
Cerebricon Appoints New Members to Board of Directors
Cerebricon Ltd. is pleased to welcome Dr Risto Lammintausta and Professor Pekka T. Männistö to its Board of Directors. Both will fill vacant positions on the board. ...
Cerebricon Announces Updates To Product Portfolio
Cerebricon Ltd. is pleased to announce the following additions to its portfolio of in vivo models: Endothelin-1 induced stroke model Stroke prone rat model (SP-SMR) for primary...
Cerebricon Ltd. Opens Business Offices in USA and UK
Dec 12, 2005 Kuopio, Finland; London, UK Cerebricon Ltd. Announces Launch of UK and USA Sales Offices In order to enhance its ability to maintain communications with current and...
Cerebricon Ltd. Poster Sessions Society for Neuroscience
CEREBRICON LTD: Announces Scientific Poster Presentations at this Years Society for Neuroscience Meeting in Washington DC, USA. Cerebricon will be exhibiting at this years SFN at Booth 438....
Cerebricon Ltd. Announces Release of New Model for Schizophrenia
Kuopio, Finland June 21st, 2005 Cerebricon Ltd., a contract rersearch organization specializing in preclinical models of CNS disease, announces the release of a new model for the study...
Cerebricon Releases Model for Spinal Cord Injury
Kuopio, Finland June 21st, 2005 Cerebricon Ltd., a contract rersearch organization specializing in preclinical models of CNS disease, announces the release of a new model for the study...
Cerebricon Ltd. Appoints New Chief Executive Officer
Cerebricon Announces Appointment of Dr Milla Koistinaho to the position of Chief Executive Officer. Effective Immediately Cerebricon is pleased to announce that Dr Milla Koistinaho will...
Cerebricon Ltd. Abstracts and Presentations for SFN 2004
Cerebricon Scientists will take part in presenting the following abstracts at the 34th Annual Meeting of the Society for Neuroscience in San Diego, October 23-27. Program# 134.10 ...
